Brown Brothers Harriman & Co. Purchases 205 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Brown Brothers Harriman & Co. raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2,928.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 212 shares of the medical research company’s stock after buying an additional 205 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Bio-Rad Laboratories were worth $70,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Metis Global Partners LLC lifted its holdings in Bio-Rad Laboratories by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock worth $234,000 after buying an additional 30 shares in the last quarter. Signaturefd LLC raised its position in shares of Bio-Rad Laboratories by 13.2% during the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company’s stock worth $87,000 after acquiring an additional 31 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 32 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Bio-Rad Laboratories by 0.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company’s stock valued at $1,488,000 after acquiring an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock worth $296,000 after purchasing an additional 34 shares during the period. 65.24% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Wells Fargo & Company reduced their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Trading Down 1.5 %

BIO opened at $239.97 on Wednesday. Bio-Rad Laboratories, Inc. has a twelve month low of $235.84 and a twelve month high of $387.99. The firm has a market cap of $6.72 billion, a PE ratio of -3.69 and a beta of 0.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The firm’s fifty day moving average is $289.28 and its two-hundred day moving average is $321.35.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.